Krebs Biochemicals and Industries Analyst Review May 2026

This Krebs Biochemicals and Industries analyst review for May 2026 covers all critical data investors need for KREBSBIO at Rs 61.81. Krebs Biochemicals and Industries is a pharmaceutical API manufacturer. This Krebs Biochemicals and Industries analyst review analyses technical levels, business fundamentals, valuation, and key risks for KREBSBIO through FY27.

Click Here – Get Free Investment Predictions

Krebs Biochemicals and Industries Analyst Review: Company Snapshot May 2026

Krebs Biochemicals produces APIs including cephalosporin intermediates and vitamins for pharmaceutical companies. The table below summarises key metrics for this Krebs Biochemicals and Industries analyst review.

Parameter	Value
NSE Ticker	KREBSBIO
Sector	Specialty Chemicals – APIs
CMP (May 2026)	Rs 61.81
52 Week High	Rs 64.90
52 Week Low	Rs 58.72
Market Cap	Rs 500 Crore
Trailing P/E	22x
Analyst Consensus Target	Rs 77.26
Bull Case Target	Rs 95.81
Bear Case Target	Rs 52.54

Analyst Insight: Krebs Biochemicals and Industries Analyst Review for FY27

Senior Research Analyst Ankit Jaiswal flags Krebs Biochemicals and Industries as a stock to watch in May 2026. At Rs 61.81, Ankit Jaiswal identifies key support in the Rs 59.89 to Rs 58.72 band and resistance near Rs 65.52. He suggests watching Krebs Biochemicals and Industries for a potential move toward Rs 77.26. Ankit Jaiswal’s view in this Krebs Biochemicals and Industries analyst review does not constitute a trade recommendation.

Technical Analysis in This Krebs Biochemicals and Industries Analyst Review

This Krebs Biochemicals and Industries analyst review places KREBSBIO at Rs 61.81 within its 52-week band of Rs 58.72 to Rs 64.90. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating KREBSBIO.

The Krebs Biochemicals and Industries analyst review identifies support in the Rs 59.89 to Rs 58.72 range and resistance in the Rs 65.52 to Rs 69.53 zone. A sustained close above Rs 65.52 could signal momentum toward the analyst consensus target of Rs 77.26.

Screen the best stocks on the Univest Screener.

Support and Resistance in This Krebs Biochemicals and Industries Analyst Review

• Support Zone: Rs 59.89 to Rs 58.72 – this Krebs Biochemicals and Industries analyst review identifies this as a potential accumulation signal for KREBSBIO.
• Resistance Zone: Rs 65.52 to Rs 69.53 – the Krebs Biochemicals and Industries analyst review flags a close above Rs 65.52 as a positive signal for KREBSBIO.
• Consensus Target: Rs 77.26 is the base-case target in this Krebs Biochemicals and Industries analyst review.

Business Segments in This Krebs Biochemicals and Industries Analyst Review

Pharmaceutical API Manufacturing

This primary segment drives revenue and margin for Krebs Biochemicals and Industries, supporting the earnings trajectory toward Rs 77.26 in this Krebs Biochemicals and Industries analyst review.

Cephalosporin Intermediates

This segment adds meaningful scale to Krebs Biochemicals and Industries’s model and is a key EPS contributor through FY27 as identified in this Krebs Biochemicals and Industries analyst review.

Vitamin and Specialty APIs

This growth frontier is a potential re-rating catalyst for KREBSBIO and a key element of this Krebs Biochemicals and Industries analyst review.

Valuation: Krebs Biochemicals and Industries Analyst Review Bull Bear Base Case

At Rs 61.81 and P/E of 22x, this Krebs Biochemicals and Industries analyst review sets three scenarios: bull case Rs 95.81, base case Rs 77.26, and bear case Rs 52.54.

Scenario	Target Price	Key Condition
Bull Case	Rs 95.81	Strong FY27 delivery and Specialty Chemicals – APIs re-rating
Base Case	Rs 77.26	Moderate growth per analyst consensus in this Krebs Biochemicals and Industries analyst review
Bear Case	Rs 52.54	Earnings miss or macro headwinds for KREBSBIO

FY27 Outlook in This Krebs Biochemicals and Industries Analyst Review

This Krebs Biochemicals and Industries analyst review for FY27 is constructive provided KREBSBIO delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor Specialty Chemicals – APIs indicators, RBI policy, and FII flow trends.

Key Risks in This Krebs Biochemicals and Industries Analyst Review

This Krebs Biochemicals and Industries analyst review identifies four key risks for KREBSBIO: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Krebs Biochemicals and Industries Analyst Review Verdict May 2026

This Krebs Biochemicals and Industries analyst review concludes that KREBSBIO at Rs 61.81 presents a defined risk-reward with consensus target Rs 77.26. The 52-week range of Rs 58.72 to Rs 64.90 provides further context. Use this Krebs Biochemicals and Industries analyst review as a research reference and consult a SEBI-registered advisor before investing in KREBSBIO.

FAQs: Krebs Biochemicals and Industries Analyst Review 2026

What is the analyst target for Krebs Biochemicals and Industries in 2026?

The Krebs Biochemicals and Industries analyst review consensus target is Rs 77.26, bull case Rs 95.81, bear case Rs 52.54.

Is Krebs Biochemicals and Industries a good buy at Rs 61.81?

At Rs 61.81 with PE 22x and target Rs 77.26, this Krebs Biochemicals and Industries analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this Krebs Biochemicals and Industries analyst review.

What is the 52-week high and low of Krebs Biochemicals and Industries?

52-week high is Rs 64.90 and 52-week low is Rs 58.72. This Krebs Biochemicals and Industries analyst review contextualises KREBSBIO at Rs 61.81 within this range.

What are the key risks for Krebs Biochemicals and Industries?

Key risks in this Krebs Biochemicals and Industries analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the Specialty Chemicals – APIs sector.

Where can I track live data for Krebs Biochemicals and Industries?

Track Krebs Biochemicals and Industries’s live price on the Univest Screener to complement this Krebs Biochemicals and Industries analyst review with real-time data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.